Fabry disease is a lysosomal storage disease arising from deficiency of the enzyme a-galactosidase A. Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease. Both contain the same human enzyme, a-galactosidase A, but they are produced using different protein expression systems and have been approved for administration at different doses. To determine if there is recognizable biochemical basis for the different doses, we performed a comparison of the two drugs, focusing on factors that are likely to influence biological activity and availability. The two drugs have similar glycosylation, both in the type and location of the oligosaccharide structures present. Differences in glycosylation were mainly limited to the levels of sialic acid and mannose-6-phosphate present, with Fabrazyme having a higher percentage of fully sialylated oligosaccharides and a higher level of phosphorylation. The higher levels of phosphorylated oligomannose residues correlated with increased binding to mannose-6-phosphate receptors and uptake into Fabry fibroblasts in vitro. Biodistribution studies in a mouse model of Fabry disease showed similar organ uptake. Likewise, antigenicity studies using antisera from Fabry patients demonstrated that both drugs were indistinguishable in terms of antibody crossreactivity. Based on these studies and present knowledge regarding the influence of glycosylation on protein biodistribution and cellular uptake, the two protein preparations appear to be functionally indistinguishable. Therefore, the data from these studies provide no rationale for the use of these proteins at different therapeutic doses.
Introduction
Fabry disease is an X-linked lysosomal storage disease arising from a deficiency of the lysosomal enzyme a-galactosidase A (EC 3.2.1.22) which cleaves terminal a-D-galactosyl residues from glycolipids (Brady et al., 1967; Kint, 1970) . Human a-galactosidase A is a homodimeric glycoprotein with three N-linked oligosaccharide chains present on each subunit. Enzyme deficiency results in a systemic lysosomal accumulation of glycolipids, primarily globotriosylceramide (GL-3) in the vascular endothelium and other tissues. In affected males, early symptoms of the disease include acroparesthesias, angiokeratoma, and corneal and lenticular opacities (Peters et al., 1997) . Over time the accumulation of glycolipid also leads to cardiovascular, cerebrovascular, and renal disease, which ultimately lead to death in the fourth or fifth decade of life.
Following initial studies which identified a-galactosidase A as the enzyme deficient in Fabry disease, early attempts were made to replace the enzyme using human a-galactosidase A from a variety of sources (Brady et al., 1973; Mapes et al., 1970) . These early studies demonstrated the potential utility of enzyme replacement therapy based on the clearance of GL-3 from the plasma of treated Fabry patients. Further progress in the treatment of this disease was limited by the lack of sufficient quantities of purified human protein.
The isolation and sequencing of the cDNA encoding human a-galactosidase A in 1986 (Bishop et al., 1986) , the production of large amounts of recombinant human enzyme (Ioannou et al., 1992) in Chinese hamster ovary (CHO) cells, and the development of a Fabry mouse model (Ohshima et al., 1997; Wang et al., 1996) provided the means to address enzyme supply issues and further explore the efficacy of enzyme replacement therapy (Ioannou et al., 2001) . These initial preclinical studies with the recombinant enzyme demonstrated that enzyme replacement therapy could clear accumulated GL-3 from both plasma and the affected tissues (kidney, spleen, and heart) of diseased animals in a dose-dependent manner.
These results, in combination with the success in treatment of Gaucher diseaseÐanother lysosomal storage diseaseÐwith recombinant human b-glucocerebrosidase (Cerezyme), led to the commercial development of two highly purified recombinant human a-galactosidase A preparations. Both have been produced by genetic engineering techniques. One form of a-galactosidase A (Fabrazyme) is produced by established recombinant engineering techniques in a CHO cell line (Ioannou et al., 1992) , as had been successfully used to produce Cerezyme. The second form (Replagal) is produced utilizing a human cell line expression system. Although some biochemical properties have been reported for a CHO-derived human a-galactosidase A (Ioannou et al., 2001) , no biochemical information is available on the commercial preparations of either the CHO or human cell line-derived human a-galactosidase A. Clinically, both products are administered by IV infusion every 2 weeks. Fabrazyme is a lyophylized powder in 35-mg vials that are reconstituted and diluted prior to infusion at a dose of 1 mg/kg every 2 weeks. Replagal is provided as liquid formulation at a concentration of 1 mg/ml in 3.5-ml vials that are diluted prior to infusion at 0.2 mg/kg every 2 weeks. The two forms of human a-galactosidase A have both been approved for treatment of Fabry disease in Europe, albeit at the different doses, and are undergoing further clinical testing and review in the United States.
Although both enzyme preparations have demonstrated efficacy in human clinical trials, the different endpoints and dosing regimens used in the trials prevent direct comparison of the relative efficacies of the two products (Pastores and Thadhani, 2002) .
Given the disparate clinical data, the lack of comparative preclinical and biochemical data, and the fact that headto-head clinical trials have not yet been reported, we conducted biochemical, pharmacological, and immunological studies of the two proteins to determine if there are significant structural and/or functional differences that could account for the different recommended doses for the two products. Because both proteins are derived from the human a-galactosidase A gene, any structural differences are likely to arise from differences in posttranslational modifications, particularly glycosylation, which can influence biodistribution, cellular uptake, stability, and potentially immunogenicity. We therefore focused this study on the comparison of posttranslational modifications and their potential impact on receptor binding, cell uptake, and biodistribution.
Results

Biochemical characterization
Because the two a-galactosidase A preparations of interest are derived from the same human DNA sequence, expressed in mammalian cells, and purified to the high degree necessary for human clinical use, any differences present would be expected to result from posttranslational modifications or degradative events during manufacturing. The biochemical analyses used in this study were therefore chosen based on their abilities to detect subtle differences in biochemical structure. As anticipated, given their origins, both products were similar in many of their biochemical properties as summarized in Tables I and II. Kinetic analysis carried out with two artificial substrates did not reveal any significant differences in the specific activity, K m , or V max between the two preparations (Table I) . Both products had a complex but comparable isoelectric focusing (IEF) banding patterns (Figure 1 ) indicating significant charge heterogeneity. The charge heterogeneity observed for both proteins on the IEF gel was significantly reduced following treatment with neuraminidase but not with phosphatase, indicating that this heterogeneity was mainly due to the presence of varying amounts of sialic acid on the enzyme molecules (data not shown).
Based on matrix-assisted laser desportion ionization timeof-flight mass spectrometry, the major species in each preparation had a monomeric molecular weight of 51.2 kDa. Each preparation also contained a minor component with a molecular weight of 47.5 kDa, which was visible on sodium (Table II) . Reversed Phase HPLC analysis gave a complex profile with both preparations having three distinct protein peaks (Figure 2) . To determine the identities of the three peaks, liquid chromatography mass spectrometry (LC/MS) analysis of tryptic digests was performed. This showed that both proteins had the predicted amino acid sequence, based on the published cDNA sequence, with the exception of the C-terminal residues. Both proteins displayed some degree of C-terminal heterogeneity with truncated species lacking either one or two C-terminal residues present in each preparation. Peak one in the chromatogram is a-galactosidase A lacking both C-terminal leucine residues, peak two is lacking a single C-terminal leucine, and peak three is the full length protein (Figure 2 ). The relative amounts of these forms differed between the two preparations; in the Replagal sample the predominant molecular species (73%) lacked the C-terminal leucine, whereas the predominant species (70%) of Fabrazyme was the full-length protein.
It is worth noting that during initial development of the CHO expression system used for production of Fabrazyme, the predominant enzyme species purified from cellconditioned medium was C-terminally truncated, missing the terminal two leucine residues. However, during the scale-up and improvement of the production process, including the implementation of additional process controls, the degree of C-terminal truncation was reduced significantly. These results suggest that the C-terminally truncated species observed in both Fabrazyme and Replagal most likely arise due to proteolytic processing of the mature full-length protein. Interestingly, it has been reported that removal of between 2 and 10 C-terminal residues resulted in up to a sixfold increase in the specific activity of a-galactosidase A toward 4-methylumbelliferyla-D-galactoside (4MU-Gal) (Miyamura et al., 1996) . However in our studies, no difference in enzymatic parameters (Table I) was observed between the preparations despite the difference in relative amounts of C-terminally truncated species.
Changes in glycosylation are known to have a significant impact on the biological properties of recombinant glycoproteins. These differences can arise as a result of cell culture conditions as well as the expression system used to produce the protein (Goochee, 1992; James et al., 1995; Jenkins and Curling, 1994; Jenkins et al., 1996) . Because protein glycosylation can have a significant impact on the efficacy of protein therapeutics, mammalian cell lines are the preferred expression system for recombinant glycoprotein production. Although both enzyme preparations are produced from the same cDNA sequence by genetic modification of mammalian cells, the cell types used are different. Fabrazyme is produced in a CHO cell line, and Replagal is produced in a human cell line of undisclosed origin. As expected, in each case the resultant protein preparations are a heterogeneous mixture of glycoforms. To determine if these two expression systems lead to different glycosylation patterns that could affect biological properties, we analyzed both the type and site-specific location of the oligosaccharide chains for each enzyme preparation.
Monosaccharide analysis (Table III) indicated that there were differences in the ratio of complex to oligomannose oligosaccharides between the two preparations. The data also showed differences in the extent of phosphorylation and sialylation of these oligosaccharides. The higher level of fucose, N-acetylglucosamine, and galactose in Replagal indicated a higher percentage of complex oligosaccharides compared with Fabrazyme. Both proteins had the same amount of sialic acid on a mole/mole of protein basis; however, the higher amount of complex chains in Replagal resulted a lower sialic acid:galactose ratio than was observed for Fabrazyme. Consequently, Replagal would be considered less completely sialylated than the Fabrazyme. An additional difference in glycosylation between the two enzymes was the amount of mannose-6-phosphate present on oligomannose side chains. Fabrazyme contained a significantly higher level of mannose-6-phosphate on a molar basis than did Replagal.
The differences in glycosylation implied by the monosaccharide compositions were confirmed by LC/MS analysis of the individual N-linked glycosylation sites. The sites of glycosylation on the two enzymes, that is, asparagine residues 108, 161, and 184, were the same. The predominant oligosaccharide species present at each of the glycosylation sites was identical for the two enzymes, although the relative ratios of these species did vary between Fabrazyme and Replagal (Table IV) . Complex oligosaccharides were observed at Asn 108 in both proteins. Though the types of complex chains present at this residue were the same for each protein, significant differences were observed in the extent of sialylation. At asparagine 161 the predominant oligosaccharide species was monophosphorylated oligomannose 7 in both proteins. However, at this site there were considerably more complex type oligosaccharides present in Replagal (52%) than Fabrazyme (25%). Likewise at asparagine 184 the major oligosaccharide species was a phosphorylated oligomannose structure, but, as observed at asparagine 161, there were more complex oligosaccharides present in Replagal (34%) than in Fabrazyme (4%). The relative distribution of sialylated and phosphorylated oligosaccharides at each glycosylation site in Replagal and Fabrazyme is shown in Table V . At all three glycosylation sites there is a higher degree of sialylation and/or phosphorylation in Fabrazyme.
The glycoform distribution on Fabrazyme is in good agreement with the previous analysis of secreted CHOexpressed recombinant human a-galactosidase A (Matsuura et al., 1998) . However, in our current studies the degree of sialylation and phosphorylation of the oligosaccharide chains is higher than that reported by Matsuura et al. (1998) . This is most likely a consequence of the different cell culture and purification conditions used in the manufacture of Fabrazyme because the controls used in largescale cell culture increase cell viability, resulting in less release of processed a-galactosidase A from lysosomes.
Receptor binding and cell uptake Based on current knowledge, one would predict that of the differences observed between the two proteins, the variation in glycosylation, in particular mannose-6-phosphate levels, had the greatest potential to influence bioactivity. This is because mannose-6-phosphate is required for both the binding of a-galactosidase A to target cells via the mannose-6-phosphate receptor and the subsequent delivery to the lysosome. To determine if the observed differences in the level of phosphorylated oligomannose chains influenced the functional activity of the proteins, we performed receptor binding and Fabry fibroblast uptake studies. Receptor binding was evaluated using surface plasmon resonance to measure the interaction of a-galactosidase A with immobilized bovine soluble cation-independent mannose-6-phosphate receptor (sCIMPR). As predicted, from the higher level of mannose-6-phosphate, substantially more Fabrazyme bound to the receptor than did Replagal at all concentrations studied ( Figure 3A) . Cell uptake studies Triantennary fucosylated monosialylated 0 7
Biantennary fucosylated monosialylated 0 9
The major oligosaccharide species at each site is indicated in bold.
demonstrated that improved binding to the mannose-6-phosphate receptor correlated with enhanced uptake of Fabrazyme into Fabry fibroblasts. Although the uptake was similar at saturating concentrations of both proteins ( Figure 3B ), Fabrazyme clearly exhibited the more potent dose-response curve of the two enzyme preparations.
Biodistribution
Based on the increased level of sialylation, Fabrazyme would be expected to have reduced clearance via the hepatic asialoglycoprotein receptor when compared to Replagal due to the lower number of exposed galactose residues. In addition, one might predict that the higher level of mannose-6-phosphate would result in increased uptake to target organs through the CIMPR-mediated pathway. To test these predictions, biodistribution studies were carried out in a Fabry knockout mouse model. Following a single IV bolus injection of 3 mg/kg of each enzyme, approximately twice as much Fabrazyme was detected in the kidney, heart, and spleen ( Figure 4 ) compared to Replagal. For each preparation, the majority (65±70%) of the injected dose was recovered in the liver (Table VI) . Because the cellular distribution within the liver was not examined, it was not possible to determine whether more Replagal was localized in hepatocytes due to increased uptake via the asialoglycoprotein receptor.
Immunoreactivity
The structural similarity between the two proteins was further investigated by comparing the immunoreactivity of each protein. The antigenicity of Fabrazyme and Replagal was compared by analyzing the cross-reactivity of antisera, derived from 22 patients treated with Fabrazyme who developed antibodies during treatment, with the two enzyme preparations. If these antibodies to Fabrazyme were generated as a result of specific immunogenic epitopes or contaminants not present in the human cell line derived sample, then it would be predicted that there would be significant difference in antibody titer when tested on the two preparations. However, as shown in Figure 5 , the antibody titer was identical for both proteins, indicating that there are no significant antigenic determinants unique to a-galactosidase A produced in CHO cells.
Discussion
For enzyme replacement therapy to be successful in the treatment of lysosomal storage disorders, it is essential that the proteins be targeted to the lysosomes of the affected tissues. That glycosylation is a key factor in this targeting process has been recognized for many years. Indeed the successful treatment of Gaucher disease is dependent on the remodeling of the oligosaccharide chains of recombinant b-glucocerebrosidase to expose mannose residues. The mannose-terminated oligosaccharide chains allow binding and uptake by the mannose receptor of tissue macrophages. The targeting strategy employed for glucocerebrosidase is not, however, applicable to the majority of lysosomal proteins because macrophages are not the primary site of substrate accumulation and most lysosomal enzymes are targeted via the mannose-6-phosphate receptor pathway. Successful targeting of these proteins is dependent on the presence of mannose-6-phosphate residues to promote uptake by the mannose-6-phosphate receptor as well as the absence of terminal galactose residues to reduce uptake by asialoglycoprotein receptor in the liver. 
Enzyme therapy for Fabry disease
With the approval in Europe of Fabrazyme and Replagal, there is now a second lysosomal storage disease that can be treated by enzyme replacement therapy. Despite the fact that the active ingredient in both products is human a-galactosidase A, they have been approved for use at different doses. Fabrazyme is recommended for use at 1 mg/kg and Replagal at 0.2 mg/kg. Because the protein sequence is the same for both products, the difference in recommended dosing most likely arises from different posttranslational modifications or is the outcome of different clinical strategies used to support product approval.
To determine if the fivefold difference in dose arises from biochemical differences between the two enzyme preparations, we performed the detailed structural and functional comparisons reported herein. Considering the different expression systems used for production, the two proteins were remarkably similar, even to the level of site-specific glycosylation. Differences were observed in the ratio of oligomannose to complex oligosaccharides at two of the three N-linked glycosylation sites and also in the levels of terminal sugar residues, with Fabrazyme having a higher percentage of phosphorylated oligomannose chains and a higher percentage of fully sialylated complex oligosaccharides. As would be expected, these differences in glycosylation resulted in improved binding of Fabrazyme to the cation-independent mannose-6-phosphate receptor, uptake into Fabry fibroblasts, and higher enzyme levels in the kidney, heart, and spleen when tested at the same dose in Fabry mice. These differences in glycosylation did not lead to different antigenic profiles that could affect efficacy because Fabry patient antibodies do not discriminate between the two proteins.
The studies reported herein demonstrate that biochemically and structurally the two enzyme preparations tested are very similar and, based on present knowledge of both Fabry disease and the role of glycosylation in protein clearance/distribution, provide no biochemical evidence to predict a fivefold difference in potency.
One of the major challenges in developing new therapies in general is the design of clinical trials that establish a new agent as both a safe and effective treatment for a particular disease. This is especially true in such diseases as the lysosomal storage disorders, for which no effective therapy exists. The limited number of patients, their often heterogeneous nature, and in some cases the slow progression of the diseases have encouraged the use of streamlined dosing strategies and surrogate endpoints to monitor clinical effects of enzyme replacement therapy. The magnitude of the challenges associated with establishing appropriate dosing are evident in the treatment of Gaucher's disease, where, despite several studies over the past 10 years, the optimal dosing regimen is still debated.
The results of the clinical trials on which Fabrazyme and Replagal were approved illustrate the difficulty of determining appropriate clinical endpoints and doses for diseases of this type (Eng et al., 2001b; Pastores and Thadhani, 2002; Schiffmann et al., 2001) . Two entirely different clinical strategies were used in gaining European approval. The Fabrazyme pivotal (phase III) clinical trial evaluated the ability of enzyme replacement therapy to clear accumulated substrate (GL-3) from the affected tissues. The dose of 1 mg/kg chosen for this trial was based on a classical dose ranging study with three dose levels and two dosing regimens (Eng et al., 2001a) . A dose-response effect was observed for all doses (0.3, 1.0, and 3 mg/kg) with respect to both GL-3 clearance and infusion reactions. The 1 mg/kg dose every 2 weeks was chosen as the optimum from a clearance standpoint while limiting the infusion reactions.
In contrast, the Replagal trial evaluated the ability of enzyme replacement to therapy to reduce the pain associated with Fabry disease (Schiffmann et al., 2001) . In this trial a dose of 0.2 mg/kg every 2 weeks was chosen. Because the phase I clinical trial for Replagal was based on a single infusion of 0.3±4.7 U/kg (0.07±0.11 mg/kg) (Schiffmann et al., 2000) , the rationale for choosing the 0.2 mg/kg dose for later studies is not clear, especially given the fact that the material used in the later studies was produced using a different expression system. Both enzyme preparations were reportedly successful in reaching the primary endpoint chosen for their respective clinical trial, but neither was as successful in meeting the primary endpoint of the other trial. Fabrazyme was successful in clearing the renal micovascular endothelium of GL-3. Although an improvement in pain score was observed, it was not significant compared to the placebo group, though it was noted that the patients were not required to discontinue their pain medications during the trial (Eng et al., 2001b) . Likewise, Replagal was reported successful in improving pain scores but was less effective in clearing GL-3. Given these disparate clinical results, there has been significant debate on the relative efficacy of the two products.
Indeed, when the clinical data for plasma GL-3 clearance are compared, both products appear to have similarly biological activity. Twelve 0.2 mg/kg infusions of Replagal reduced plasma GL-3 by 50% (Schiffmann et al., 2001) compared to a 70±90% reduction following 5 0.3 mg/kg infusions of Fabrazyme (Eng et al., 2001a) and a 100% reduction following 11 infusions at 1 mg/kg (Eng et al., 2001b) . These data suggest that plasma GL-3 clearance is dose-dependent and that equivalent reduction in GL-3 levels are seen with both enzyme preparations.
The GL-3 clearance data in conjunction with the biochemical analysis reported here support structural and functional equivalence of the two proteins. This suggests that the different dosing regimens currently used for the two preparations in Europe are a result of the different clinical trial designs rather than a functional difference between the two proteins.
Materials and methods
a-Galactosidase A To perform a valid comparison of representative lots, clinical product commercially available in Europe was used for these studies. For Fabrazyme (Genzyme, Cambridge, MA), lot number 607725 was used and the vial reconstituted according to the package instructions to give a nominal protein concentration of 5 mg/ml. The Replagal (Transkaryotic Therapies, Cambridge, MA) lot used was FG901-005-01 with a labeled concentration of 1 mg/ml. Prior to biochemical analysis the protein concentration for each product was determined using a high-performance liquid chromatography (HPLC)-based concentration assay calibrated with a recombinant human a-galactosidase A control of a known concentration, determined by amino acid analysis. The measured concentration of each (Fabrazyme 4.92 mg/ml and Replagal 0.79 mg/ml) was used for the biochemical analyses while the labeled concentration was used for the in vivo analysis.
Reversed-phase HPLC Reversed-phase HPLC analysis was performed using a YMC 2.1 Â 100 mm octyl column maintained at a temperature of 40 C. Protein (7.5 mg load) was eluted using a linear trifluoracetic acid/acetonitrile gradient at a flow rate of 0.25 ml/min with UV detection at 280 nm.
IEF
Ten micrograms of each protein were loaded on a pH 3±7 IEF gel run with premade buffer (Invitrogen, Carlsbad, CA).
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Focusing was for 1 h at 100 V, 1 h at 200 V, and 30 min at 500 V. Gels were stained for 1 h with PhastGel Coomassie Blue R-350 (Pharmacia, Uppsala, Sweden) and destained for 2 h in methanol/acetic acid.
Specific activity and kinetic measurements
Specific activities of the two enzymes were measured by the hydrolysis of the artificial substrates 4MU-Gal (Bishop and Desnick, 1981) and p-nitrophenyl-a-D-galactopyranoside (pNP-Gal) at 37 C at pH 4.6 in 20 mM citrate, 30 mM sodium phosphate, 0.1% bovine serum albumin, 0.67% ethanol, 0.02% sodium azide. For 4MU-Gal, the reaction was carried out at a substrate concentration of 10 mM and quenched after 15 min with NaOH and fluorescence read (excitation 365 nm, emission 460 nm) against a 4MU standard curve. For pNP-Gal, the reaction was carried out at a substrate concentration of 33 mM and quenched after 10 min with NaOH and the absorbance at 405 nm determined. Kinetic parameters for each substrate were based on measurements at five concentrations and Eadie-Hofstee plots were used to calculate K m and V max .
Monosaccharide analysis
Samples were dialyzed into 50 mM sodium phosphate pH 7.0, then 80 mg were removed and hydrolyzed in 2 M trifluoroacetic acid at 100 C for 2 h. Samples were cooled, evaporated, reconstituted in HPLC-grade water, and filtered through a 0.45-mm centrifugal filter (Durapore filters produced by Millipore, Bedford, MA). Analysis was performed using high-pH anion exchange chromatography with pulsed amperometric detection (Dionex). Mannose-6-phosphate was analyzed using a 10-min linear gradient of 170±400 mM sodium acetate in 100 mM NaOH on a CarboPacPA10 column (Dionex Corp, Sunnyvale, CA). For sialic acid, hydrolysis was performed in 0.5 M formic acid at 80 C for 1 h, and elution was with a 20-min linear gradient of 50±180 mM sodium acetate in 100 mM NaOH. Galactose, N-acetylglucosamine, mannose, and fucose were measured using a CarboPacPA1 column and Amino Trap precolumn (Dionex), and elution was with 200 mM sodium hydroxide over 45 min. Quantitation was performed relative to the appropriate monosaccharide standard curve. Mannose-6-phosphate and N-acetylneuraminic acid were from Sigma (St. Louis, MO); D-galactose, D-mannose, Nacetylglucosamine, and L-fucose were from Pfanstiehl Laboratories (Waukegan, IL).
LC/MS analysis
Samples were reduced and alkylated with 4-vinylpyridine (Sigma) prior to overnight digestion with Endoproteinase Lys-C (Roche, Indianapolis, IN) at a 1:25 enzyme:protein ratio. Digests (0.6 mg) were loaded onto a 320 mm Â 150 mm Vydac C 18 column and peptides eluted with a linear gradient of acetonitrile in 1% formic acid at a flow rate of 4 ml/min. The eluant was fed directly into the electrospray source of a Bruker Esquire ion-trap mass spectrometer. For calculating glycoform distribution, spectra were averaged across the glycopeptide peak, and the amount of each glycoform was calculated as percentage of total response.
Receptor binding
The relative affinities for the sCIMPR were determined by surface plasmon resonance (BIAcor AB, Uppsala, Sweden). sCIMPR purified from fetal bovine serum was immobilized on a CM5 chip via the primary amine groups of lysine residues. Samples were serially diluted to 20, 10, 5, 2.5, 1.25, 0.63, and 0.31 mg/ml in 10 mM HEPES, pH 7.4, 3 mM ethylenediamine tetra-acetic acid, 150 mM NaCl, and 0.005% Tween 20. Binding was determined following a 3-min injection at a flow rate of 20 ml/min. The sCIMPR surface was regenerated prior to the next injection with two 30-s injections of 300 mM NaCl, 10 mM sodium citrate, pH 5.0, at a flow rate of 75 ml/min.
Fibroblast uptake
Fabry fibroblasts (NIGMS Coriell Institute) were seeded in 48-well plates at 1 Â 10 4 cells/well in Earle's modified Eagle's medium (MEM), 10% fetal bovine serum, 1% MEM vitamin mix, 1% MEM nonessential amino acids, and 2% amino acids (Gibco, Gaithersburg, MD) and incubated overnight at 37 C and 5% CO 2 . Serial dilutions of samples were added to the cells and incubated for 24 h at 37 C. Following incubation, medium was aspirated and the cells lysed by freeze thawing. The activity of the cell lysates was determined at pH 4.4 using 4MU-Gal. Total protein content of the cell lysates was determined using a BCA total protein assay (Pierce, Rockford, IL).
Biodistribution
Three-month-old mice lacking the a-galactosidase A gene (Wang et al., 1996) were dosed intravenously with 3 mg/kg of each enzyme via the tail vein. Tissue samples were placed on ice, 10 volumes of lysate buffer (14.5 mM citric acid, 30 mM sodium phosphate, 0.15% Triton-X100, pH 4.4) added, and tissues homogenized for approximately 1 min using an IKA Ultra-Turrax T8 homogenizer set at approximately 25,000 rpm. Homogenates were centrifuged at 3500 rpm for 10 min at 4 C, and the supernatants were transferred to clean test tubes and centrifuged again at 3500 rpm for 5 min. Serial dilutions of tissue homogenate supernatant were prepared and assayed for aGAL activity using the pNP-Gal substrate.
Immunoreactivity with patient serum Microtiter plates (96 well) plates were coated with a 5 mg/ml solution of either Fabrazyme or Replagal. After coating, plates were blocked with a 0.1% solution of human serum albumin in phosphate buffered saline and dilutions of Fabry patient serum added to the plates and incubated for 1 h. Plates were washed and binding of a-galactosidase A-specific antibodies detected using goat anti-human IgG-horseradish peroxidase. Orthophenylenediamine substrate was added to each plate and titer determined by measuring the absorbance at 490 nm.
